tiprankstipranks
Trending News
More News >
Owens & Minor (OMI)
NYSE:OMI
Advertisement

Owens & Minor (OMI) AI Stock Analysis

Compare
536 Followers

Top Page

OMI

Owens & Minor

(NYSE:OMI)

Rating:43Neutral
Price Target:
$5.00
▼(-7.41% Downside)
Owens & Minor's overall stock score reflects significant financial and technical challenges. The company's weak financial performance and bearish technical indicators are the most impactful factors. Valuation concerns further weigh down the score. While strategic shifts and corporate events offer some positive outlook, they are overshadowed by the current financial instability and market sentiment.
Positive Factors
Sale of P&HS Segment
The sale of the Products and Healthcare Solutions (PHS) segment is expected to be accretive, potentially significantly.
Share Price Potential
Despite challenges, analyst recommendation remains Buy/High Risk, with an expected share price return of 51.2%.
Valuation and Cash Flow
Valuation is supported by a solid cash flow quarter, providing some downside protection for OMI.
Negative Factors
Loss of Kaiser Contract
The loss of the Kaiser contract is expected to create growth headwinds for OMI in 2026.
Rotech Deal Termination Costs
The termination of the Rotech deal has costs that will slow near-term debt paydown by approximately $100MM.
Stranded Costs and Margins
Stranded costs from the P&HS business remain elevated and are expected to increase further, impacting margins negatively.

Owens & Minor (OMI) vs. SPDR S&P 500 ETF (SPY)

Owens & Minor Business Overview & Revenue Model

Company DescriptionOwens & Minor, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States and internationally. It operates through two segments, Global Solutions and Global Products. The Global Solutions segment offers a portfolio of products and services to healthcare providers and manufacturers. Its portfolio of medical and surgical supplies includes branded products and its proprietary products. This segment also offers services to healthcare providers, which include supplier management, analytics, inventory management, and clinical supply management; and various programs to provide logistics and marketing solutions to its suppliers. The Global Products segment manufactures and sources medical surgical products for the prevention of healthcare-associated infections across the acute and alternate site channels. This segments products portfolio includes sterilization wraps, surgical drapes and gowns, facial protection products, protective apparel, medical exam gloves, custom and minor procedure kits, and other medical products. It provides its products and services to multi-facility networks of healthcare providers, independent hospitals, surgery centers, physicians' practices, and networks of hospitals directly, as well as indirectly through third-party distributors. The company was founded in 1882 and is headquartered in Richmond, Virginia.
How the Company Makes MoneyOwens & Minor generates revenue primarily through the distribution of medical and surgical supplies to healthcare providers, including hospitals, clinics, and nursing homes. The company's revenue model is based on the sale of products and services, with key revenue streams including the sale of medical supplies, logistics and supply chain management services, and contract distribution agreements with healthcare organizations. Additionally, Owens & Minor has established partnerships with various medical manufacturers, allowing them to offer a wide range of products while benefiting from favorable pricing agreements. The company's focus on value-added services, such as inventory management and customized supply chain solutions, also contributes to its earnings by enhancing customer satisfaction and loyalty.

Owens & Minor Earnings Call Summary

Earnings Call Date:Aug 11, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 29, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a mix of positive and negative elements. The company highlighted strong growth in the Patient Direct business and improved EBITDA margins. However, challenges included significant costs associated with the Rotech acquisition termination and increased stranded costs, alongside slower-than-expected growth in the diabetes segment. Overall, the sentiment appears balanced with both positive and negative aspects influencing the outlook.
Q2-2025 Updates
Positive Updates
Patient Direct Business Growth
The Patient Direct business has grown significantly since its acquisition in 2017, with projected revenue between $2.76 billion and $2.82 billion and adjusted EBITDA range of $376 million to $382 million in 2025.
Adjusted EBITDA Improvement
For the second quarter, adjusted EBITDA was $96.6 million or 14.2% margin rate compared to $91.1 million or 13.8% margin rate in the second quarter of 2024, driven by volume growth, improved collection rate, favorable product mix, productivity gains, and lower benefit costs.
Strong Category Performance
Sleep, ostomy, and urology categories showed strong growth, with sleep supplies leading the overall growth rate.
Successful Cash Flow Management
Cash provided from operating activity in Q2 was $38 million, reversing the cash used in operating activity in Q1, driven by working capital reduction and improved collection rates.
Negative Updates
Rotech Acquisition Termination Costs
$80 million in expenses from the termination of the Rotech acquisition and $18 million in Rotech-related financing costs in the second quarter.
Diabetes Segment Challenges
Revenue growth was lower than expected due to modifications in customer ordering quantities and delivery frequency for diabetes supplies, with expected rebound remaining below prior year due to the shift from DME to pharmacy.
Increased Stranded Costs
Stranded costs impacting adjusted EBITDA include approximately $11 million in the second quarter of 2025, with expectations for these costs to rise before falling due to some lost economies of scale.
Company Guidance
During the Owens & Minor second-quarter 2025 earnings call, the company provided guidance for the full year, projecting revenue between $2.76 billion and $2.82 billion and adjusted EBITDA ranging from $376 million to $382 million, exclusive of the divested Products & Healthcare Services (P&HS) segment. The Patient Direct business, which is now the company's primary focus, demonstrated growth, with revenue for the quarter reaching $682 million, marking a 3.3% increase from the previous year. Adjusted EBITDA for Q2 was $96.6 million, reflecting a margin rate improvement from 13.8% to 14.2% compared to Q2 2024. Despite a lower-than-expected growth rate, partly due to supplier disruptions, the company anticipates a rebound in the diabetes category later in the year. Owens & Minor also highlighted a strong performance in sleep supplies, urology, and ostomy, attributing overall EBITDA growth to volume increases, improved collection rates, and a favorable product mix. Stranded costs, which impacted adjusted EBITDA, were $11 million for the quarter, with expectations of a rise following the anticipated near-term completion of the P&HS divestiture. The company plans to utilize the proceeds from the sale to reduce debt, targeting a leverage ratio of 2x to 3x EBITDA, while continuing to explore selective acquisition opportunities to bolster the Patient Direct business.

Owens & Minor Financial Statement Overview

Summary
Owens & Minor faces significant profitability challenges despite revenue growth, with negative net income impacting overall financial health. The high leverage and fluctuating cash flow pose risks, necessitating focused management strategies to enhance profitability and stabilize cash flows.
Income Statement
45
Neutral
Owens & Minor's revenue has shown a steady growth trajectory, with a notable increase over the past years. However, profitability metrics reveal challenges, with negative EBIT and net income in the most recent TTM period. The gross profit margin remains stable, but the negative net profit margin highlights ongoing operational struggles.
Balance Sheet
50
Neutral
The balance sheet reflects a high debt-to-equity ratio, suggesting significant leverage. Although the equity ratio indicates a solid proportion of assets financed by equity, the return on equity is negative, driven by consistent net losses, indicating financial stress.
Cash Flow
40
Negative
Cash flow analysis shows fluctuating free cash flow, with a negative trend in the most recent TTM. The operating cash flow to net income ratio indicates that cash from operations is relatively unaffected by net losses, providing some liquidity cushion. The negative free cash flow to net income ratio suggests cash flow generation challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue8.73B10.70B10.33B9.96B9.79B8.48B
Gross Profit1.98B2.22B2.13B1.83B1.51B1.28B
EBITDA-90.76M51.22M400.29M367.80M415.46M277.41M
Net Income-1.20B-362.69M-41.30M22.39M221.59M29.87M
Balance Sheet
Total Assets4.15B4.66B5.09B5.39B3.54B3.34B
Cash, Cash Equivalents and Short-Term Investments38.26M49.38M243.04M69.47M55.71M83.06M
Total Debt463.98M2.14B2.32B2.70B1.15B1.14B
Total Liabilities4.44B4.09B4.17B4.44B2.60B2.62B
Stockholders Equity-281.01M565.23M924.17M945.60M938.50M712.05M
Cash Flow
Free Cash Flow-156.05M-66.67M532.82M158.42M74.49M280.03M
Operating Cash Flow100.85M161.50M740.71M325.01M124.18M339.22M
Investing Cash Flow-180.61M-116.53M-137.25M-1.80B-53.63M80.07M
Financing Cash Flow-118.21M-267.60M-417.33M1.50B-129.48M-379.39M

Owens & Minor Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.40
Price Trends
50DMA
6.94
Negative
100DMA
7.05
Negative
200DMA
9.13
Negative
Market Momentum
MACD
-0.45
Negative
RSI
43.64
Neutral
STOCH
80.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMI, the sentiment is Neutral. The current price of 5.4 is above the 20-day moving average (MA) of 5.36, below the 50-day MA of 6.94, and below the 200-day MA of 9.13, indicating a neutral trend. The MACD of -0.45 indicates Negative momentum. The RSI at 43.64 is Neutral, neither overbought nor oversold. The STOCH value of 80.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OMI.

Owens & Minor Risk Analysis

Owens & Minor disclosed 47 risk factors in its most recent earnings report. Owens & Minor reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Owens & Minor Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
$8.29B21.5911.18%2.29%14.98%
70
Outperform
-0.85%-23.40%
66
Neutral
$86.03B27.6051.23%0.43%20.35%11.96%
60
Neutral
$57.16B30.33130.60%0.75%11.56%5.31%
59
Neutral
$35.71B23.18-43.80%1.35%-1.94%85.70%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
43
Neutral
$411.71M-144.11%-17.10%-2720.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
OMI
Owens & Minor
5.40
-10.09
-65.14%
COR
Cencora
292.70
59.67
25.61%
CAH
Cardinal Health
149.34
39.30
35.71%
HSIC
Henry Schein
67.78
-1.03
-1.50%
MCK
McKesson
691.45
189.51
37.76%
PDCO
Patterson Companies
31.33
10.89
53.28%

Owens & Minor Corporate Events

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Owens & Minor Reports Q2 Results Amid Segment Sale
Positive
Aug 11, 2025

On August 11, 2025, Owens & Minor reported its second-quarter financial results, highlighting the classification of its Products & Healthcare Services segment as discontinued operations due to an impending sale. The company’s continuing operations, primarily the Patient Direct segment, showed solid performance and growth, with revenue increasing to $681.9 million from $660.4 million in the same quarter of the previous year. Despite a net loss from continuing operations, the adjusted net income and EBITDA showed improvement, reflecting the company’s strategic focus on the Patient Direct business. CEO Ed Pesicka expressed optimism about the company’s future as a pure-play Patient Direct business, supported by favorable demographic trends.

The most recent analyst rating on (OMI) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.

M&A TransactionsBusiness Operations and StrategyRegulatory Filings and Compliance
Owens & Minor Ends Merger with Rotech Healthcare
Negative
Jun 5, 2025

On June 3, 2025, Owens & Minor, Inc. and Rotech Healthcare Holdings Inc. mutually agreed to terminate their merger agreement, with Owens & Minor paying an $80 million termination fee to Rotech. The decision was influenced by regulatory challenges and the company will now focus on growing its Patient Direct business and deleveraging, while exploring potential sales of its Products and Healthcare Services business.

The most recent analyst rating on (OMI) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Owens & Minor Shareholders Approve Key Governance Decisions
Neutral
May 16, 2025

On May 15, 2025, Owens & Minor, Inc. held its Annual Meeting of Shareholders where key decisions were made. The shareholders elected nine directors for a one-year term and ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. Additionally, an advisory vote approved the compensation of the company’s named executive officers. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (OMI) stock is a Sell with a $18.00 price target. To see the full list of analyst forecasts on Owens & Minor stock, see the OMI Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 14, 2025